صحافة بلادي صحيفة إلكترونية مغاربية متجددة على مدار الساعة تعنى بشؤون المغرب الجزائر ليبيا موريتانيا تونس
On Thursday, August 14, 2025, the Ministry of Health and Population expressed its appreciation for the report issued byAgencyFitch credit rating in August 2025, which praised the strategic steps taken by Egypt to strengthen the pharmaceutical industry.
The report confirmed that the reformsEconomicThe comprehensive and extensive regulatory updates implemented by the state contributed to creating an attractive investment environment, which strengthened Egypt’s position as a leading regional center for the pharmaceutical industry in the Middle East and North Africa region.
The report indicated that thisRepairsIt attracted major international companies to the Egyptian market, enhancing confidence in the stability of the economic and regulatory environment in the long term. He highlighted the important regulatory transformations, especially the reduction of drug registration periods from 3 to 5 years to a period ranging between two and six months, which allowed international companies to accelerate the launch of their products and increase registration applications.
The report explained the continuation of the marketEgyptianIn promoting local manufacturing and technology transfer, despite the challenges associated with investment in research and development. In this context, he noted that in 2024 the Egyptian government signed three financing agreements with the European Union worth 36 million euros to support the manufacture of vaccines and the development of scientific research, praising the legal framework regulating clinical trials, including Law No. 214 of 2020 and its Executive Regulations No. 927 of 2022, which enhance ethical supervision and protection of participants.
The report also addressed the health and demographic achievements associated with the increasing demand for medicines, pointing to Egypt’s efforts to confront the challenges resulting from growthPopulationAnd high rates of non-communicable diseases through presidential initiatives for early detection and awareness. He praised the sustainable achievements in combating infectious diseases, as the World Health Organization declared Egypt free of malaria, measles and rubella, with significant progress towards eliminating hepatitis C and B.
As highlightedReportNational efforts to combat diabetes through monitoring and early diagnosis campaigns, updating treatment guidelines, and implementing the “STEPwise” survey, in addition to distributing 3,000 HbA1c testing devices to primary health care units to ensure unified standards of care based on scientific evidence.
The report indicated a noticeable decline in the fertility rate, from 3.44 births per woman in 2015 to 2.10 births in 2023, supported by the expansion of reproductive health services and the rise in ratesEducationIncreasing women’s participation in the labor market.
With regard to cancer, the report indicated that early detection initiatives, the most prominent of which is the PresidentRepublicTo support Egyptian women’s health, which was launched in 2019, it achieved about 60 million visits, which reflects the rise in health awareness and contributed to reducing the percentage of advanced cases (third and fourth stages) by 58.9% to 29%. The report also mentioned doubling state allocations for cancer treatment from 1.8 billion pounds in 2020-2021 to 3.6 billion pounds in 2023-2024, with continued investment in the infrastructure of the oncology sector.
As for hepatitis C, the report confirmed thatEgyptIn October 2023, it achieved “gold level” classification from the World Health Organization, reflecting its commitment to reducing infection and mortality rates, and getting closer to the complete elimination of the disease before 2030.
And in the HIV fileHumanity(AIDS), the report indicated a low prevalence rate in Egypt compared to the region, with free antiretroviral treatment provided to all patients through a wide network of specialized government centers, without interruption in the availability of medicines during the past six years, which indicates the sustainability of the health care system.
